Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Left behind? Drug discovery in extensive-stage small-cell lung cancer

Jonathan W Riess1, Primo N Lara1

  • 1University of California Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA.

Clinical Lung Cancer
|February 18, 2014
PubMed

Insights

Outcomes for extensive-stage small-cell lung cancer (SCLC) patients remain poor. A new drug development approach focusing on tumor biology, not empiricism, is needed to improve SCLC therapeutics.

Area of Science:

  • Oncology
  • Translational Medicine
  • Cancer Therapeutics

Background:

  • Extensive-stage small-cell lung cancer (SCLC) has seen no significant improvement in systemic therapy or survival for 25 years.
  • Current treatment paradigms for SCLC are largely empirical, leading to limited therapeutic advancements.

Purpose of the Study:

  • To advocate for a paradigm shift in SCLC drug development.
  • To explore novel therapeutic strategies by focusing on tumor biology and heterogeneity.
  • To leverage advancements from non-small-cell lung cancer (NSCLC) research for SCLC treatment.

Main Methods:

  • Review of current SCLC treatment limitations.
  • Analysis of successful drug development strategies in NSCLC.
  • Proposal for a biology-driven approach to SCLC drug discovery.

Main Results:

  • Current empirical approaches in SCLC have failed to improve patient survival.
  • Tumor biology and heterogeneity offer potential targets for novel SCLC therapies.
  • Incorporating NSCLC research tools could accelerate SCLC therapeutic development.

Conclusions:

  • A new, biology-focused drug development paradigm is essential for improving SCLC outcomes.
  • Targeting tumor biology and heterogeneity can increase drug and target diversity for SCLC.
  • Adoption of advanced tools and strategies from NSCLC research offers hope for future SCLC therapeutics.
Keywords:
AmrubicinChemotherapyClinical trialsDevelopmental therapeuticsSmall cell lung cancer

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

559

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K